The canonical Wnt/β‐catenin signaling pathway and Wnt ligands have been associated with numerous bone metabolic disorders and diseases,(7, 8) and also play an important role in osteoblastogenesis and the regulation of bone metabolism.(9, 10) Soluble Wnt antagonists, such as dickkopf‐1 (DKK1) and sclerostin (SOST), are critical components of this pathway and inhibit bone formation when secreted locally by osteoblasts (OBs), bone marrow stromal cells (BMSCs), and osteocytes. The gene discussed is SOST; the disease is metabolic bone disorder.